News

Novozymes plans new research facility

Novozymes has signed a deal to acquire a 140,000 square metre site in Lyngby. The site is located 13 kilometres north of Copenhagen, close to the highway to Elsinore and seven kilometers from its headquarters in Bagsværd, where the company plans to build a new campus dedicated to research and business development. “This is an […]

Novozymes has signed a deal to acquire a 140,000 square metre site in Lyngby. The site is located 13 kilometres north of Copenhagen, close to the highway to Elsinore and seven kilometers from its headquarters in Bagsværd, where the company plans to build a new campus dedicated to research and business development.

“This is an investment in the future, where the new innovation campus will be a cornerstone for our global research,” said Per Falholt, Executive Vice President for R&D at Novozymes. “Novozymes is driven by innovation and this center will help strengthen our growth through developing ground-breaking biotechnology.”

Approximately 14% of Novozymes’ revenue is reinvested into research annually, the company says, leading to the development of over 100 new products since the company went public 15 years ago. These products are said to be used globally and enable energy-efficient production, replacement of fossil fuels, more sustainable food production and other benefits.

“With the location in Lyngby, in close proximity to the Technical University of Denmark our ambition is to create a global hub for biotech research,” said Falholt. “Our new campus will be important in creating the ultimate conditions for product development while simultaneously offering our employees a great workplace.”

As part of the campus construction, Novozymes says it will also establish a learning centre where students and visitors alike are invited to discover and learn about the magic of nature and biology. The learning centre will include teaching laboratories, a small cinema and a cafe, and will function as a link to the research environment in Lyngby.

More than 20% of Novozymes’ 6,500 employees work within research and development, according to the company.  In Denmark, Novozymes employs 2,700 people – a number that has grown by approximately 600 since 2005. This growth is said to have contributed to the decision to develop the new innovation campus.

The inauguration of the new innovation campus is expected to take place in 2018.